vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $180.9M, roughly 1.1× AVANOS MEDICAL, INC.). ROGERS CORP runs the higher net margin — 2.2% vs -0.7%, a 3.0% gap on every dollar of revenue. On growth, ROGERS CORP posted the faster year-over-year revenue change (5.2% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $1.1M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -3.3%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
AVNS vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $200.5M |
| Net Profit | $-1.3M | $4.5M |
| Gross Margin | 47.5% | 32.2% |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 2.2% |
| Revenue YoY | 0.7% | 5.2% |
| Net Profit YoY | 99.7% | 421.4% |
| EPS (diluted) | $-0.02 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $180.9M | $201.5M | ||
| Q3 25 | $177.8M | $216.0M | ||
| Q2 25 | $175.0M | $202.8M | ||
| Q1 25 | $167.5M | $190.5M | ||
| Q4 24 | $179.6M | $192.2M | ||
| Q3 24 | $170.4M | $210.3M | ||
| Q2 24 | $171.7M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-1.3M | $4.6M | ||
| Q3 25 | $-1.4M | $8.6M | ||
| Q2 25 | $-76.8M | $-73.6M | ||
| Q1 25 | $6.6M | $-1.4M | ||
| Q4 24 | $-397.3M | $-500.0K | ||
| Q3 24 | $4.3M | $10.7M | ||
| Q2 24 | $1.8M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 47.5% | 31.5% | ||
| Q3 25 | 48.4% | 33.5% | ||
| Q2 25 | 52.6% | 31.6% | ||
| Q1 25 | 53.6% | 29.9% | ||
| Q4 24 | 54.6% | 32.1% | ||
| Q3 24 | 54.5% | 35.2% | ||
| Q2 24 | 55.7% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 3.5% | ||
| Q3 25 | 0.1% | 7.3% | ||
| Q2 25 | -42.6% | -33.3% | ||
| Q1 25 | 6.1% | -0.2% | ||
| Q4 24 | -233.0% | -6.6% | ||
| Q3 24 | 7.0% | 6.9% | ||
| Q2 24 | 3.7% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -0.7% | 2.3% | ||
| Q3 25 | -0.8% | 4.0% | ||
| Q2 25 | -43.9% | -36.3% | ||
| Q1 25 | 3.9% | -0.7% | ||
| Q4 24 | -221.2% | -0.3% | ||
| Q3 24 | 2.5% | 5.1% | ||
| Q2 24 | 1.0% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.02 | $0.20 | ||
| Q3 25 | $-0.03 | $0.48 | ||
| Q2 25 | $-1.66 | $-4.00 | ||
| Q1 25 | $0.14 | $-0.08 | ||
| Q4 24 | $-8.64 | $-0.04 | ||
| Q3 24 | $0.09 | $0.58 | ||
| Q2 24 | $0.04 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $195.8M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.2B |
| Total Assets | $1.1B | $1.4B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $89.8M | $197.0M | ||
| Q3 25 | $70.5M | $167.8M | ||
| Q2 25 | $90.3M | $157.2M | ||
| Q1 25 | $97.0M | $175.6M | ||
| Q4 24 | $107.7M | $159.8M | ||
| Q3 24 | $89.0M | $146.4M | ||
| Q2 24 | $92.2M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $778.2M | $1.2B | ||
| Q3 25 | $778.0M | $1.2B | ||
| Q2 25 | $776.3M | $1.2B | ||
| Q1 25 | $839.4M | $1.3B | ||
| Q4 24 | $828.5M | $1.3B | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.2B | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $5.8M |
| Free Cash FlowOCF − Capex | $21.3M | $1.1M |
| FCF MarginFCF / Revenue | 11.8% | 0.5% |
| Capex IntensityCapex / Revenue | 3.8% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $28.2M | $46.9M | ||
| Q3 25 | $14.0M | $28.9M | ||
| Q2 25 | $6.8M | $13.7M | ||
| Q1 25 | $25.7M | $11.7M | ||
| Q4 24 | $57.9M | $33.7M | ||
| Q3 24 | $23.0M | $42.4M | ||
| Q2 24 | $27.8M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $21.3M | $42.2M | ||
| Q3 25 | $7.0M | $21.2M | ||
| Q2 25 | $-4.2M | $5.6M | ||
| Q1 25 | $19.0M | $2.1M | ||
| Q4 24 | $53.1M | $18.3M | ||
| Q3 24 | $20.0M | $25.2M | ||
| Q2 24 | $21.9M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 11.8% | 20.9% | ||
| Q3 25 | 3.9% | 9.8% | ||
| Q2 25 | -2.4% | 2.8% | ||
| Q1 25 | 11.3% | 1.1% | ||
| Q4 24 | 29.6% | 9.5% | ||
| Q3 24 | 11.7% | 12.0% | ||
| Q2 24 | 12.8% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 3.8% | 2.3% | ||
| Q3 25 | 3.9% | 3.6% | ||
| Q2 25 | 6.3% | 4.0% | ||
| Q1 25 | 4.0% | 5.0% | ||
| Q4 24 | 2.7% | 8.0% | ||
| Q3 24 | 1.8% | 8.2% | ||
| Q2 24 | 3.4% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 3.96× | ||
| Q2 24 | 15.44× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
ROG
Segment breakdown not available.
